• Je něco špatně v tomto záznamu ?

Mortality prediction after transcatheter treatment of failed bioprosthetic aortic valves utilizing various international scoring systems: Insights from the Valve-in-Valve International Data (VIVID)

M. Aziz, M. Simonato, JG. Webb, M. Abdel-Wahab, D. McElhinney, A. Duncan, D. Tchetche, M. Barbanti, AS. Petronio, F. Maisano, VG. Ribeiro, DF. Gaia, R. Rana, V. Kocka, M. Mathur, H. Wijeysundera, F. Hellig, H. Nissen, R. Bekeredjian, C. Rihal,...

. 2018 ; 92 (6) : 1163-1170. [pub] 20180805

Jazyk angličtina Země Spojené státy americké

Typ dokumentu srovnávací studie, časopisecké články, multicentrická studie, pozorovací studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc19045322

BACKGROUND: Transcatheter Aortic Valve Implantation (TAVI) is commonly used to deploy new bioprosthetic valves inside degenerated surgically implanted aortic valves in high risk patients. The three scoring systems used to assess risk of postprocedural mortality are: Logistic EuroSCORE (LES), EuroSCORE II (ES II), and Society of Thoracic Surgeons (STS). OBJECTIVE: The purpose of this study is to analyze the accuracy of LES, ES II, and STS in estimating all-cause mortality after transcatheter aortic valve-in-valve (ViV) implantations, which was not assessed before. METHODS: Using the Valve-in-Valve International Data (VIVID) registry, a total of 1,550 patients from 110 centers were included. The study compared the observed 30-day overall mortality vs. the respective predicted mortalities calculated by risk scores. The accuracy of prediction models was assessed based on calibration and discrimination. RESULTS: Observed mortality at 30 days was 5.3%, while average expected mortalities by LES, ES II and STS were 29.49 (± 17.2), 14.59 (± 8.6), and 9.61 (± 8.51), respectively. All three risk scores overestimated 30-day mortality with ratios of 0.176 (95% CI 0.138-0.214), 0.342 (95% CI 0.264-0.419), and 0.536 (95% CI 0.421-0.651), respectively. 30-day mortality ROC curves demonstrated that ES II had the largest AUC at 0.722, followed by STS at 0.704, and LES at 0.698. CONCLUSIONS: All three scores overestimated mortality at 30 days with ES II showing the highest predictability compared to LES and STS; and therefore, should be recommended for ViV procedures. There is a need for a dedicated scoring system for patients undergoing ViV interventions.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19045322
003      
CZ-PrNML
005      
20200113104954.0
007      
ta
008      
200109s2018 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/ccd.27714 $2 doi
035    __
$a (PubMed)30079597
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Aziz, Mina $u St. Paul's Hospital, Vancouver, Canada.
245    10
$a Mortality prediction after transcatheter treatment of failed bioprosthetic aortic valves utilizing various international scoring systems: Insights from the Valve-in-Valve International Data (VIVID) / $c M. Aziz, M. Simonato, JG. Webb, M. Abdel-Wahab, D. McElhinney, A. Duncan, D. Tchetche, M. Barbanti, AS. Petronio, F. Maisano, VG. Ribeiro, DF. Gaia, R. Rana, V. Kocka, M. Mathur, H. Wijeysundera, F. Hellig, H. Nissen, R. Bekeredjian, C. Rihal, SJ. Duffy, D. Dvir,
520    9_
$a BACKGROUND: Transcatheter Aortic Valve Implantation (TAVI) is commonly used to deploy new bioprosthetic valves inside degenerated surgically implanted aortic valves in high risk patients. The three scoring systems used to assess risk of postprocedural mortality are: Logistic EuroSCORE (LES), EuroSCORE II (ES II), and Society of Thoracic Surgeons (STS). OBJECTIVE: The purpose of this study is to analyze the accuracy of LES, ES II, and STS in estimating all-cause mortality after transcatheter aortic valve-in-valve (ViV) implantations, which was not assessed before. METHODS: Using the Valve-in-Valve International Data (VIVID) registry, a total of 1,550 patients from 110 centers were included. The study compared the observed 30-day overall mortality vs. the respective predicted mortalities calculated by risk scores. The accuracy of prediction models was assessed based on calibration and discrimination. RESULTS: Observed mortality at 30 days was 5.3%, while average expected mortalities by LES, ES II and STS were 29.49 (± 17.2), 14.59 (± 8.6), and 9.61 (± 8.51), respectively. All three risk scores overestimated 30-day mortality with ratios of 0.176 (95% CI 0.138-0.214), 0.342 (95% CI 0.264-0.419), and 0.536 (95% CI 0.421-0.651), respectively. 30-day mortality ROC curves demonstrated that ES II had the largest AUC at 0.722, followed by STS at 0.704, and LES at 0.698. CONCLUSIONS: All three scores overestimated mortality at 30 days with ES II showing the highest predictability compared to LES and STS; and therefore, should be recommended for ViV procedures. There is a need for a dedicated scoring system for patients undergoing ViV interventions.
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a aortální chlopeň $x patofyziologie $x chirurgie $7 D001021
650    12
$a bioprotézy $7 D001705
650    12
$a metody pro podporu rozhodování $7 D003661
650    _2
$a ženské pohlaví $7 D005260
650    12
$a srdeční chlopně umělé $7 D006350
650    _2
$a chirurgická náhrada chlopně $x škodlivé účinky $x přístrojové vybavení $x mortalita $7 D019918
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a prediktivní hodnota testů $7 D011237
650    _2
$a protézy - design $7 D011474
650    12
$a selhání protézy $7 D011475
650    _2
$a registrace $7 D012042
650    _2
$a hodnocení rizik $7 D018570
650    _2
$a rizikové faktory $7 D012307
650    _2
$a časové faktory $7 D013997
650    _2
$a transkatetrální implantace aortální chlopně $x škodlivé účinky $x přístrojové vybavení $x mortalita $7 D065467
650    _2
$a výsledek terapie $7 D016896
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a pozorovací studie $7 D064888
700    1_
$a Simonato, Matheus $u St. Paul's Hospital, Vancouver, Canada. Escola Paulista de Medicina - UNIFESP, São Paulo, Brazil.
700    1_
$a Webb, John G $u St. Paul's Hospital, Vancouver, Canada.
700    1_
$a Abdel-Wahab, Mohamed $u Segeberger Kliniken, Bad Segeberg, Germany.
700    1_
$a McElhinney, Doff $u Stanford University School of Medicine, Stanford, California.
700    1_
$a Duncan, Alison $u Royal Brompton Hospital, London, United Kingdom.
700    1_
$a Tchetche, Didier $u Clinique Pasteur, Toulouse, France.
700    1_
$a Barbanti, Marco $u Ferrarotto Hospital, Catania, Italy.
700    1_
$a Petronio, Anna Sonia $u Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.
700    1_
$a Maisano, Francesco $u University Hospital Zürich, Zürich, Switzerland.
700    1_
$a Ribeiro, Vasco Gama $u Centro Hospitalar Vila Nova de Gaia, Vila Nova de Gaia, Portugal.
700    1_
$a Gaia, Diego Felipe $u Escola Paulista de Medicina - UNIFESP, São Paulo, Brazil.
700    1_
$a Rana, Ruhina $u St. Paul's Hospital, Vancouver, Canada.
700    1_
$a Kocka, Viktor $u Third Faculty of Medicine - Charles University, Prague, Czech Republic.
700    1_
$a Mathur, Moses $u University of Washington, Seattle, Washington.
700    1_
$a Wijeysundera, Harindra $u Sunnybrook Hospital, Toronto, Canada.
700    1_
$a Hellig, Farrel $u Sunninghill Hospital, Johannesburg, Republic of South Africa.
700    1_
$a Nissen, Henrik $u Odense University Hospital, Odense, Denmark.
700    1_
$a Bekeredjian, Raffi $u University Hospital Heidelberg, Heidelberg, Germany.
700    1_
$a Rihal, Charanjit $u Mayo Clinic, Rochester, Minnesota.
700    1_
$a Duffy, Stephen J $u The Alfred Hospital, Melbourne, Australia.
700    1_
$a Dvir, Danny $u St. Paul's Hospital, Vancouver, Canada. University of Washington, Seattle, Washington.
773    0_
$w MED00005333 $t Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions $x 1522-726X $g Roč. 92, č. 6 (2018), s. 1163-1170
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30079597 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200109 $b ABA008
991    __
$a 20200113105326 $b ABA008
999    __
$a ok $b bmc $g 1483591 $s 1083995
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 92 $c 6 $d 1163-1170 $e 20180805 $i 1522-726X $m Catheterization and cardiovascular interventions $n Catheter Cardiovasc Interv $x MED00005333
LZP    __
$a Pubmed-20200109

Najít záznam

Citační ukazatele

Možnosti archivace